CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 280 enrolled
Drug / intervention
Lebrikizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03443024
NCT03443024Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company·interventional·Posted Feb 22, 2018·Updated May 4, 2021

In Brief

A Phase 2 clinical trial evaluating Lebrikizumab and Placebo for Atopic Dermatitis. Completed, enrolled 280 participants across 58 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsDermira, Inc.

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 22, 2018
Enrollment StartJan 30, 2018
Primary CompletionFeb 7, 2019
Study CompletionMay 23, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.4 years ago

Interventions

Lebrikizumabbiological

Sterile liquid solution administered subcutaneously.

Placebodrug

Solution administered subcutaneously.